Clinical Trial Update: Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease [Phase 2]

View source ↗

Summary

Phase 2 trial update comparing twice-weekly intravenous micafungin pharmacokinetics to daily dosing in patients at risk for invasive fungal disease; study compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Allogeneic Stem Cell Transplant
• Graft-versus-host Disease
• Myelodysplastic Syndrome

Drugs mentioned

• Micafungin (micafungin)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Acute Graft Versus Host Disease Grade II-IV, Allogeneic Stem Cell Transplant | Phase 2 | Status: COMPLETED